Valuation : Insmed Incorporated

Market Cap 26.51B 22.76B 21.3B 19.51B 36.75B 2,532B 36.85B 252B 98.62B 1,276B 99.53B 97.38B 4,223B P/E 2026 *
-76.7x
P/E 2027 * 112x
Enterprise Value 25.88B 22.21B 20.8B 19.04B 35.87B 2,471B 35.97B 246B 96.27B 1,246B 97.16B 95.06B 4,122B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 8.78x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-2.41%
1 week-2.95%
Current month+23.11%
1 month+15.91%
3 months+14.09%
6 months-18.71%
Current year-30.25%
1 week 121.21
Extreme 121.21
127.18
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Fiscal year

Chief Operating Officer

719,550 0.3320%
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
-2.41%-2.95%-9.77%+455.82% 27.16B
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.39% 65.4B
-1.03%+0.46%+8.14%-5.28% 28.28B
+0.79%-0.29%+63.82%+12.38% 26.57B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.37%+1.21%+36.55%-15.78% 20.09B
-1.72%-4.28%+13.44%+531.90% 15.87B
-1.50%+2.92%+43.50%+151.30% 13.9B
-0.59%+1.28%+306.56%+217.41% 12.59B
Average -0.09%+1.36%+84.20%+196.51% 30.09B
Weighted average by Cap. +0.66%+0.95%+66.97%+158.19%

Financials

2026 *2027 *
Net sales 1.81B 1.55B 1.45B 1.33B 2.5B 173B 2.51B 17.19B 6.72B 86.95B 6.78B 6.64B 288B 2.89B 2.48B 2.32B 2.12B 4B 276B 4.01B 27.46B 10.74B 139B 10.84B 10.6B 460B
Net income -349M -300M -281M -257M -484M -33.37B -486M -3.32B -1.3B -16.82B -1.31B -1.28B -55.66B 211M 181M 170M 156M 293M 20.19B 294M 2.01B 787M 10.18B 794M 777M 33.68B
Net Debt -632M -542M -508M -465M -876M -60.34B -878M -6.01B -2.35B -30.41B -2.37B -2.32B -101B -1.16B -993M -930M -851M -1.6B -110B -1.61B -11.01B -4.3B -55.67B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-27 US$121.39 -2.41% 1,056,199
26-08-26 US$124.39 +0.40% 1,979,984
26-08-25 US$123.89 -0.07% 2,373,321
26-08-24 US$123.98 -1.42% 1,341,042
26-08-21 US$125.77 +0.55% 1,124,491
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
121.39USD
Average target price
200.18USD
Spread / Average Target
+64.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock